论文部分内容阅读
目的观察树突状细胞共培养细胞因子诱导的杀伤细胞(DC-CIK)联合培美曲塞或吉西他滨单药化疗治疗老年晚期非小细胞肺癌患者的疗效及安全性。方法选取90例老年晚期非小细胞肺癌患者,随机将其分为两组。对照组行培美曲塞或吉西他滨单药化疗治疗,研究组在对照组基础上行DC-CIK的生物免疫疗法,两组各45例。对比两组临床治疗效果及安全性。结果研究组疾病控制率(85.36%)明显高于对照组(63.97%)(χ~2=7.95,P<0.05),但两组客观缓解率并无显著差异(χ~2=1.96,P>0.05)。对照组出现14例血小板减少,5例出现肝功能受损严重;研究组出现10例血小板减少,其不良反应发生率(22.22%)明显低于对照组(42.22%)(χ2=8.94,P<0.05)。结论相比单一药物化疗治疗,DC-CIK联合培美曲塞或吉西他滨单药化疗能够提高老年晚期非小细胞肺癌患者的临床疗效,可提高疾病控制率,亦能够降低不良反应发生率,安全性较高,值得临床上进一步推广和应用。
Objective To observe the efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with pemetrexed or gemcitabine monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Ninety elderly patients with advanced non-small cell lung cancer were selected and randomly divided into two groups. The control group received pemetrexed or gemcitabine monotherapy, and the study group received DC-CIK bioimmunotherapy on the basis of the control group, 45 cases in each group. Compare the clinical efficacy and safety of two groups. Results The disease control rate (85.36%) in the study group was significantly higher than that in the control group (63.97%, χ ~ 2 = 7.95, P <0.05), but there was no significant difference between the two groups (χ ~ 0.05). The thrombocytopenia occurred in 14 cases in the control group, and 5 cases showed severe hepatic dysfunction. In the study group, 10 cases had thrombocytopenia. The incidence of adverse reactions in the control group was significantly lower than that in the control group (22.22% vs 42.22%, χ2 = 8.94, P < 0.05). Conclusion Compared with single drug chemotherapy, DC-CIK combined with pemetrexed or gemcitabine monotherapy can improve the clinical efficacy of elderly patients with advanced non-small cell lung cancer, improve disease control rate, and can reduce the incidence of adverse reactions, safety Higher, it is worth further clinical application and application.